Short Interest in Humacyte, Inc. (NASDAQ:HUMA) Expands By 5.3%

Humacyte, Inc. (NASDAQ:HUMA) was the target of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 3,980,000 shares, a growth of 5.3% from the March 15th total of 3,780,000 shares. Based on an average daily volume of 968,700 shares, the days-to-cover ratio is presently 4.1 days. Approximately 4.6% of the shares of the stock are sold short.

Humacyte Stock Up 2.0 %

HUMA stock opened at $3.12 on Thursday. The firm has a 50-day moving average price of $3.52 and a 200-day moving average price of $2.97. Humacyte has a 12 month low of $1.96 and a 12 month high of $5.60. The company has a current ratio of 4.52, a quick ratio of 4.52 and a debt-to-equity ratio of 1.20. The stock has a market capitalization of $371.54 million, a P/E ratio of -2.92 and a beta of 1.46.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings data on Friday, March 22nd. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.01. During the same quarter in the prior year, the company posted ($0.21) earnings per share. As a group, equities research analysts anticipate that Humacyte will post -0.9 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Piper Sandler reissued a “neutral” rating and issued a $4.00 target price on shares of Humacyte in a report on Tuesday, March 26th. Cantor Fitzgerald restated an “overweight” rating and set a $7.00 price objective on shares of Humacyte in a research report on Monday, April 1st. Finally, Benchmark reaffirmed a “buy” rating and issued a $15.00 target price on shares of Humacyte in a report on Monday, March 25th.

Institutional Investors Weigh In On Humacyte

Hedge funds have recently modified their holdings of the company. UBS Asset Management Americas Inc. increased its holdings in Humacyte by 17.3% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 15,947 shares of the company’s stock worth $51,000 after purchasing an additional 2,347 shares in the last quarter. Legal & General Group Plc increased its stake in shares of Humacyte by 24.7% in the second quarter. Legal & General Group Plc now owns 16,970 shares of the company’s stock valued at $55,000 after buying an additional 3,364 shares during the period. Susquehanna International Group LLP raised its holdings in Humacyte by 16.2% in the 1st quarter. Susquehanna International Group LLP now owns 31,367 shares of the company’s stock valued at $97,000 after buying an additional 4,372 shares during the last quarter. UBS Group AG boosted its position in Humacyte by 92.0% during the 3rd quarter. UBS Group AG now owns 9,827 shares of the company’s stock worth $32,000 after buying an additional 4,710 shares during the period. Finally, Osaic Holdings Inc. grew its holdings in Humacyte by 16.3% during the 2nd quarter. Osaic Holdings Inc. now owns 33,985 shares of the company’s stock worth $97,000 after acquiring an additional 4,775 shares during the last quarter. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).